Keywords: Urinary trypsin inhibitor; metastasis; chemotherapy Tumour cell invasion is required for tumour cell entry into the vascular system and for extravasation in distant organs.
An increased production of proteolytic enzymes including urokinase-type plasminogen activator (uPA), plasmin, cathepsins and collagenases has been associated with the invasive and metastatic potential of tumour cells (Liotta et al., 1983; Dano et al., 1985) . It has been reported that protease inhibitors, specific antibodies for these enzymes and inhibition of the urokinase receptor may prevent cancer cell invasion (Crowley et al., 1993; Kobayashi et al., 1993) .
Urinary trypsin inhibitor (UTI), which is one of the physiological trypsin inhibitors, was isolated and purified from human urine. Besides trypsin, UTI exhibits a multipotent inhibitory effect on such proteases as plasmin, human leucocyte elastase, chymotrypsin, and hyaluronidase (Wachter and Hochstrasser, 1981; Albrecht et al., 1983; Balduyck et al., 1989; Gebhard et al., 1990) . In previous studies, we demonstrated that UTI inhibited production of experimental and spontaneous pulmonary metastasis by murine Lewis lung carcinoma (3LL) cells (Kobayashi et al., 1995a) . In addition,
the effective peptide (R-A-F-I-Q-L-W-A-F-D-A-V-K-G-K),
representing the amino acid sequences within the plasmininhibiting domain of the UTI molecule, inhibited both in vitro tumour cell invasion through basement membrane Matrigel and in vivo 3LL cell lung metastasis in C57BL/6 mice. Briefly, in an in vivo assay, multiple s.c. injections of UTI (500;Lg mouse-' day-') for at least 7 days immediately after (Burgers et al., 1989; Saiki et al., 1993a,b) . 10,l15,20,23,30,36,39,42,44,53,59,62 ,0,0,0,0,0,5,10,13,21,36,36,40,41 Experinent 7 (Figure 7) The effect of etoposide alone in treatment was demonstrated. Tumour nodules were allowed to grow and each group (n = 9) underwent etoposide treatment usig the same treatment schedules and doses as used for experiments 5 and 6. The surgical excision of primary tumour was not performed.
Statistical analysis
The data were analysed for sign by the Wilcoxon test.
Res
Effect ofsurgical excision of twnour at various times on lung metastatic spread of 3LL cells Surgery was performed on days 7, 14 or 21 after s.c. tumour cell inoculation (Figure 1 ). Two mice (experiment 1, regimen b) were lost from the study. These animals died within 24 h of surgery from surgically related haemorrhage. Otherwise, there was no surgical failure at the site of surgical resection. Controls were not operated upon (Figure la) . The effect of various times of surgery was evaluated with respect to the number of lung tumour colonies. Note that the number of lung tumour colonies in mice receiving surgery on day 21 was significantly increased compared with those mice without operation (P = 0.0017; Figure la) . Microscopic lung metastasis was established by day 14 after s.c. tumour cell inoculation (data not shown) and surgical treatment alone on or after day 14 might result in no cures (Figure lb and c) . Also, surgery performed on day 14 did not reduce the number of lung tumour colonies (P = 0.7965; Figure lc) . On the other hand, surgery performed on day 7 siifintly reduced the number of lung tumour colonies (P = 0.0001; Figure Id) 00, 0, 0, 5, 11, 18, 19, 20, 24, 26, 29, 30, 30, 31, 33 (Figure 2 ; regmen c). Fifty-five animals were randomised into four groups and we examined the effect of combination therapy on lung metastass ( Figure 5 ). The combination treatment (Figure 5d ) reduced the number of lung tumour colonies significantly compared with the untreated control (P=0.0059; Figure 5a ), suggesting that the combination group (Figure 5d ) will show signifiantly prolonged survival periods. No benefit was noted with UTI single therapy compared with untreated controls (P= 0.1097; Figure 5b vs a). Etoposide alone did not lead to a reduced metastatic spread (P = 0.0890; Figure  5c vs a).
In addition, based on the demonstration that 14 days of tumour growth produced microscopic lung mtastasis even in those mice that received surgery, we tested the effects of UTI and chemotherapy in this system (Figure 6 ; which can be viewed as advanced stage of cancers). Mice were randomised into four groups as described above. Etoposide when used as a single agent demonstrated some tumour growth inhibition, since three mice had no evidence of metastatic lung colonies.
The combination treatment (Figure 6d (Ossowski and Reich. 1980, 1983; Ostrowski et al., 1986; Hearing et al., 1988; Ossowski, 1988 (Kobayashi et al., 1995) .
The possibility of UTI acting as an anti-metastatic agent has been reported (Kobayashi et al., 1994a, d) . According to our previous reports, UTI's enhancement of anti-metastatic activity may result from its inhibitory effects on cellassociated plasmin activity (Kobayashi et al., 1994d) , and that UTI efficiently regulates the mechanism involved not only in the entry into vascular circulation of tumour cells (intravasation) through, at least in part, inhibition of the proteolytic enzyme, plasmin, but also in the extravasation step, during the metastatic process (Kobayashi et al., 1994d (Kobayashi et al., , 1995 . Since UTI has no anti-tumour activity, however, UTI treatment alone resulted in excessive growth of primary tumour and no cures. To provide a therapeutically promising basis for the prevention of cancer metastasis, we examined the effects of UTI in combination with etoposide on antitumor activity (Burgers et al., 1989; Saiki et al., 1993a, b In the 3LL model, surgery alone on day 7 may improve the survival time by removing tumours before many cells had extravasated. In the early stage of cancer, the administration of UTI in combination with surgery on day 7 did not inhibit lung metastasis. In the group of animals which received surgical excision of the primary tumours on day 14 however, multiple administrations of UTI (days 0-6 and days 14-20) significantly inhibited spontaneous lung metastasis. Note that the number of lung tumour colonies of mice receiving surgery on day 21 was significantly increased compared with those without operation, suggesting that resection of large primary tumours may increase more shedding at surgery (Burgers et al., 1989) .
The The exact mechanism of action of UTI is still unclear, but it is thought that UTI inhibits cell-associated plasmin activity. In addition, our previous studies provide novel information on the plasma membrane UTI-specific binding sites on some tumour cells including 3LL cells (Kobayashi et al., 1994J) . UTI is not an integral membrane glycoprotein but is bound to a specific surface receptor that is incompletely saturated. Bound UTI retains its protease inhibiting activity (plasmin and trypsin inhibiting activities; our unpublished data).
We suggest a model for the proposed interaction of UTI and receptors on the surface of invading tumour cells as follows: Plasmin(ogen) attaches to plasmin(ogen) receptor on the cell surface and it allows the tumour cells to invade extracellular matrix. UTI, exogenously added to the cells, attached to its receptor on the tumour cell surface efficiently inhibits plasmin activity in the close environment of the cells and thus it contributes to prevent tumour cell invasion and metastasis. UTI may play a regulatory role in uPA/plasmindependent tumour cell invasion and metastasis. Thus, UTI might provide a therapeutically promising basis for the prevention of tumour metastasis as an anti-metastatic agent.
In general, the clinical application of an agent such as UTI may be fraught with difficulty. It is likely that prolonged administration would be necessary with all the ensuing consequences. The experimental schedules used in this study would not reveal these potential problems. However, the molecule is unlikely to be antigenic, since UTI is therapeutically promising for the treatment of acute pancreatitis in Japan. 
